Studies how calaspargase pegol affects blood clotting in children with leukemia
Observes blood clotting effects of calaspargase pegol in children with lymphoblastic leukemia.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- 31 Jul 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Non-Interventional Study
- Record updated
- 13 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with acute lymphoblastic leukemia or lymphoma who are planned to get treatment with Cal-PEG.
- Age
- 2 to 21.5 years
- Sex
- All sexes
- Disease stage
- Confirmed acute lymphoblastic leukemia/lymphoma
- Earlier treatment
- Treatment with Cal-PEG must be planned. No systemic blood thinner within 48 hours before the study blood draw.
Main reasons for not taking part
- Coagulation disorders that were there before
- Known hypersensitivity to asparaginase products
- Liver failure
- Any acute or chronic disease known to affect coagulation testing (for example nephrotic syndrome)
- Currently pregnant
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 2-21.5 years
- Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
- Planned treatment with Cal-PEG
- Informed consent obtained from parents or guardians
Who cannot take part
- Use of systemic blood thinner within 48 hours prior to study blood draw
- Pre-existing coagulation disorders
- Known hypersensitivity to asparaginase products
- Liver failure
- Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
- Currently pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 22 years old?
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Clinical TrialsTaking people
About the trial
What the trial wants to find out
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
The group in the trial
- Observational
Patients undergo collection of blood samples and have their medical records reviewed on study.
Treatment: Non-Interventional Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
- Plain-language title
- Studies how calaspargase pegol affects blood clotting in children with leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07071051, who can take part
- Record updated
- 13 February 2026